Exelixis

NCT00570635

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

NCT00704288

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

NCT00940225

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

NCT01068782

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

NCT01441947

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

NCT01428219

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

NCT01639508

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

NCT01811212

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

NCT01835145

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

NCT01954745

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

NCT01995058

Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

NCT01630590

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

NCT02036476

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

NCT02260531

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

NCT02132598

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

NCT02795156

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

NCT03213626

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

NCT03316586

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

NCT03541902

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

NCT03468218

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

NCT03534804

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

NCT04022343

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

NCT03899155

Pan Tumor Rollover Study

NCT04197310

Cabozantinib and Nivolumab for Carcinoid Tumors

NCT04164979

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

NCT04091750

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

NCT03964337

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

NCT04230954

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

NCT04289779

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

NCT04322955

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

NCT04472767

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT04413123

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

NCT04412629

Cabozantinib in High Grade Neuroendocrine Neoplasms

NCT04551430

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

NCT04631744

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04442581

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

NCT04876456

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

NCT04963283

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

NCT05052723

Cabozantinib and Pembrolizumab in Metastatic Pancreas

NCT05263050

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

NCT05425004

Cabozantinib for Patients With Recurrent or Progressive Meningioma

NCT05200143

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

NCT05135975

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

NCT05048212

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

NCT05502315

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

NCT05039736

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

NCT05931393

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

NCT06568562

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06698250

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

NCT05859217

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

NCT06959511

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

NCT07043608

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

NCT06926634

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

NCT06794229

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

NCT07185945

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

NCT06863311

Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

NCT07193550

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

NCT07218666

Zanzalintinib in Men With Aggressive Variant Prostate Cancer